Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 247

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 4
Chunk 247
---
 the market value of our Class A common stock could decline significantly. 

The market price of our Class A common stock may be volatile, which could result in substantial losses for investors.

The trading price of our Class A common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this report, these factors include:

•the timing of our launch of future products and degree to which the launch and commercialization thereof meets the expectations of securities analysts and investors;

•changes in the structure or funding of research at academic and research laboratories and institutions, including changes that would affect their ability to purchase our instruments or consumables;

•the success of existing or new competitive businesses or technologies;

•announcements about new research programs or products of our competitors;

•general economic, industry and market conditions;

•volatility and variations in market conditions in the life sciences sector generally, or the genomics sector specifically;

•whether our financial results meet our publicly announced expectations or the expectations of securities analysts or investors;

•actual or anticipated changes in our estimates as to our financial results or development timelines, variations in our financial results or those of companies that are perceived to be similar to us or changes in estimates or recommendations by securities analysts, if any, that cover our Class A common stock or companies that are perceived to be similar to us;

•investor perceptions of us or our industry;

•the level of expenses related to any of our research and development programs or products;

•litigation and governmental investigations involving us, our industry or both;

68

•the outcomes of and related rulings in the litigation and administrative proceedings in which we are currently or may in the future become involved;

•developments or disputes concerning patent applications, issued patents or other proprietary rights;

•the recruitment or departure of key personnel;

•regulatory or legal developments in the United States and other countries;

•the announcement or expectation of additional financing efforts;

•stock-based compensation expense;

•the failure or discontinuation of any of our product development and research programs;

•sales of our Class A common stock or Class B common stock by us, our insiders or other stockholders;

•natural disasters, infectious diseases, conflict, war, civil unrest, epidemics or pandemics or resurgences or major catastrophic events; and

•the other factors described in this “Risk Factors” section.

In